BiotechTube
TTC Oncology

TTC Oncology

San Diego, United States· Est.
ttconcology.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

TTC Oncology is a clinical-stage biotechnology company focused on developing TTC-352, a novel ShERPA (Selective Human Estrogen Receptor Partial Agonist) for the treatment of metastatic ER+ breast cancer. The company was founded by a team of academic experts and is built on a worldwide license from the University of Illinois Chicago (UIC). Its core strategy is to address the significant unmet need in endocrine-resistant breast cancer by offering a safer alternative to high-dose estrogen therapy, with the drug having already completed a Phase 1 clinical trial.

OncologyBreast Cancer

Technology Platform

ShERPA (Selective Human Estrogen Receptor Partial Agonist) platform for modulating the estrogen receptor to treat endocrine-resistant ER+ breast cancer with an improved safety profile.

Opportunities

TTC-352 addresses a large, persistent unmet need in endocrine-resistant metastatic ER+ breast cancer, a population with limited safe treatment options.
Success could position the drug as a valuable later-line therapy in a multi-billion dollar global market.
The company's strong academic foundation and completed Phase 1 trial provide a credible platform for partnership or further investment.

Risk Factors

The company faces high clinical risk as TTC-352's efficacy in pivotal trials is unproven.
It has extreme concentration risk with only one clinical asset and is dependent on raising additional capital to fund development.
It also operates in the highly competitive and rapidly evolving breast cancer therapeutics landscape.

Competitive Landscape

TTC-352 competes in the crowded ER+ breast cancer space, facing competition from standard endocrine therapies, CDK4/6 inhibitors, PI3K inhibitors, SERDs (like elacestrant), and other novel agents. Its primary differentiation is its mechanism as a safer estrogen receptor agonist aimed specifically at overcoming endocrine resistance, a niche not directly addressed by most newer targeted therapies.

More companies in Small Molecule Drugs →More companies in United States →